Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Meredith S. Irwin, Arlene Naranjo, Fan F. Zhang, +14

Journal of Clinical Oncology

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

Rajen Mody, Alice L. Yu, Arlene Naranjo, +16

Journal of Clinical Oncology

Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study

Kevin X. Liu, Arlene Naranjo, Fan F. Zhang, +12

Journal of Clinical Oncology

A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study

Brian Weiss, Gregory A. Yanik, Arlene Naranjo, +17

Pediatric Blood & Cancer

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report

Navin Pinto, Arlene Naranjo, Xiangming Ding, +13

Clinical Cancer Research

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

Amy K. Erbe, Mitch B Diccianni, Rajen Mody, +17

Journal for ImmunoTherapy of Cancer

Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification

Hannah Bender, Meredith S. Irwin, Michael D. Hogarty, +7

Journal of Clinical Oncology